{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"11"}],"title":"Very Good Partial Response (VGPR)"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Expired at 1 year"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"This measure will record the number of subjects for each grade of response to therapy for subjects with Systematic Disease (hematologic) only. Hematologic response will be determined as follows.\n\nComplete response (CR) - Negative serum/urine immunofixation with normal Free Light Chain (FLC) ratio\n\nVery Good Partial Response (VGPR)- Difference between involved and uninvolved FLCs (dFLC) \\< 40 mg/L\n\nPartial Response (PR)- dFLC decrease \\> 50%\n\nNo Response (NR)- less then PR.","groups":[{"description":"Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.\n\nDoxycycline: Doxycycline will be continued until one of the following criteria is met:\n\n* Patient has completed 1 year of doxycycline therapy\n* Patient develops any grade 3-4 toxicity related to doxycycline use.","id":"OG000","title":"Doxycycline (Systemic Disease)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Hematologic response is not relevant to subjects with localized disease. Subjects with localized disease were not included in this analysis. Five participants had expired by the 1 year time point","reportingStatus":"POSTED","timeFrame":"1 year","title":"Hematologic Response","type":"PRIMARY","unitOfMeasure":"Participants"}